ArticleBosnian journal of basic medical sciences2020
Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases.
Article in Bosnian journal of basic medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer.Biomedicines · 2026Review
- PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report.Frontiers in oncology · 2026Article
- Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.BMC cancer · 2024Article
- Article
- PD-L1 testing by immunohistochemistry in immuno-oncology.Biomolecules & biomedicine · 2023Review
- Nanoparticles overcome adaptive immune resistance and enhance immunotherapyFrontiers in pharmacology · 2023Review
- Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastases-a Single-Center Study in 190 Patients.JTO clinical and research reports · 2022Article
- An integrated biomarker of PD-L1 expression and intraepithelial CD8Thoracic cancer · 2022Article
- Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles.Neuro-oncology advances · 2021Article
- Tumor immune microenvironment in brain metastases from gynecologic malignancies.Cancer immunology, immunotherapy : CII · 2021Article
- An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer.Translational lung cancer research · 2021Article
- Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study.Frontiers in oncology · 2021Article
- Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis.Neuro-oncology advancesReview
- Quantitative Analysis of CD27/CD70 Protein Expression and Investigation of Related Mechanisms in the Tumor Microenvironment of NSCLC.In vivo (Athens, Greece)Article
- Genomic drivers of brain metastases in lung cancer.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed death-ligand 1 (PD-L1) is suggested to be a predictive biomarker in non-small-cell lung carcinoma (NSCLC). However, the differential expression of PD-L1 in primary lung tumor vs. synchronous metastases, especially brain metastasis (BM), remains unclear. This study assessed the concordance of PD-L1 expression on tumor cells and tumor-infiltrating lymphocytes (TILs) and CD8+ TIL intensity between primary lung tumors and synchronous BMs from 24 NSCLC patients. PD-L1, CD3, and CD8 positivity was determined by immunohistochemistry (IHC). PD-L1 scoring was based on the proportion of tumor cells with membranous expression of PD-L1 and the cutoff values <1%, 1-49%, and ≥50%. CD3 and CD8 positivity in TILs was evaluated semi-quantitatively and the proportion of CD3+/CD8+ TILs was determined. PD-L1 expression on tumor cells and TILs was evaluated in relation to CD3+/CD8+ TIL proportions and the intensity of CD8+ TILs between the paired primary lung and BM tissues. In the primary lung tumors, PD-L1 positivity was observed in 25%, 37.5%, and 37.5% cases for the cutoff values <1%, 1-49%, and ≥50%, respectively. PD-L1 expression on tumor cells was strongly correlated between the paired primary lung and BM tissues, in all cutoff groups. However, PD-L1 expression on TILs and the proportion of CD3+/CD8+ TILs were not strongly correlated in all three groups between the paired primary lung tumors and BMs. The intensity of CD8+ TILs was concordant in only 54.16% of the paired primary lung tumors and BMs. This study showed a high concordance of PD-L1 expression in neoplastic cells between primary NSCLC and synchronous BMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.